This product is an oral selective histamine H1 receptor antagonist. It has no obvious anticholinergic and anti-5-hydroxytryptamine effects, and has a small central nervous system inhibitory effect.

Inhibit the synthesis of prostaglandins, stop the formation of pain nerve impulses in inflammatory tissues, and inhibit inflammatory responses, including inhibiting the chemotaxis of leukocytes and the release of lysosomal enzymes.

It is incorporated into bone tissue earlier, promoting the synthesis of polysaccharide compounds, increasing the viscosity of synovial fluid, and improving and repairing the metabolism of articular cartilage.

It selectively blocks alpha 1 receptors and has a highly selective blocking effect on the smooth muscles of the urethra, bladder neck and prostate, relaxes the smooth muscles, reduces urethral compression, and its ability to inhibit the increase in urethral pressure is 13 times its ability to inhibit the increase in vasodilation pressure; it improves urination disorders, reduces the prostate pressure in the urethral pressure curve, and has no effect on rhythmic bladder contractions and the bladder pressure curve.

Nimodipine is a Ca2 channel blocker that can inhibit smooth muscle contraction to relieve vasospasm. It has a strong effect on cerebral arteries, is highly lipophilic, and can easily pass through the blood-brain barrier, protecting and promoting memory and intellectual recovery. It selectively acts on cerebral vascular smooth muscle, dilates cerebral blood vessels, increases cerebral blood flow, and reduces ischemic brain damage.